Remove 2023 Remove Communication Remove Controlled Substances Remove Labelling
article thumbnail

Telemedicine and the Prescribing of Controlled Substances After the End of The Covid-19 Pandemic Emergency: DEA Announces Two Significant Proposed Rules: Read the Summary Below, But Learn All the Details and More at HPM’s Webinar on March 23, 2023 (Details Forthcoming….)

The FDA Law Blog

Palmer — The 2008 Ryan Haight Online Pharmacy Consumer Protection Act placed strict limits on online prescribing or the use of telemedicine encounters to prescribe controlled substances. That emergency declaration is set to expire on May 11, 2023. By Karla L. 21 U.S.C. §

article thumbnail

OPDP Comes out Swinging With A Warning Letter on Unsubstantiated Efficacy

The FDA Law Blog

Prior to the CytoDyn letter in 2022, OPDP issued a Warning Letter in 2021 to CooperSurgical for a DTC video entitled “Paragard: Family Planning During the Pandemic” which failed to communicate ANY risk information. This seems to suggest that FDA expects this type of outcome claim to be included in labeling. But a Warning Letter?

FDA 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Zolpidem interactions to avoid

The Checkup by Singlecare

The Food and Drug Administration (FDA) even sent a special communication to call attention to this risk. The Drug Enforcement Administration (DEA) categorizes zolpidem as a controlled substance, meaning that it has significant potential for abuse. For that reason, it is typically best to avoid combining opiates with zolpidem.

article thumbnail

Testosterone side effects and how to avoid them

The Checkup by Singlecare

Some healthcare providers may prescribe it off-label for erectile dysfunction or to women for certain conditions. The FDA has classified testosterone drugs as Schedule III controlled substances because of their potential for abuse and dependency. It’s also used to treat teen males with delayed puberty.

FDA 52